Under the expanded deal, PredictImmune will have first right of refusal on technologies for predicting disease outcome for systemic lupus erythematosus.
Addenbrooke' Hospital will manage and facilitate the fulfillment orders of the firm's PredictSure IBD orders, as well as receive and process all samples.
Inhibiting the associated protein, PAI-1, appeared to ease inflammation and symptoms in a mouse model of inflammatory bowel disease.
Genome- and exome-wide association analysis on inflammatory bowel disease patients with or without thiopurine-induced myelosuppression revealed new and known risk genes.
In PLOS this week: microRNAs linked to brain metastasis risk in lung cancer, effects of Crohn's disease-linked mutation, and more.
The test is a 15-biomarker quantitative PCR panel used to stratify patients with Crohn's disease and ulcerative colitis based on the severity of their illness.
By achieving certification for the assay, called PredictSure IBD, the Cambridge, UK-based firm can sell it for clinical use across Europe.
In adults and children with Crohn's, miR-31 was found at higher levels in gut tissue, and the cases marked by lower expression tended to have poorer outcomes.
The companies aim to develop microbiome diagnostic assays for colon cancer and other gastrointestinal diseases including irritable bowel syndrome.
PredictImmune's test relies on a 16-marker panel run using quantitative PCR to stratify Crohn's disease and ulcerative colitis patients according to the severity of their illnesses.
New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.
A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.
Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.
In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.